Biotech News <http://tech.groups.yahoo.com/group/biotech-news/> GPC Biotech Announces that Partner Pharmion Submits European Marketing Application for Satraplatin GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; Nasdaq: GPCB) today announced that its partner, Pharmion Corporation (Nasdaq: PHRM), has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for satraplatin in combination with prednisone for the treatment of patients with metastatic hormone refractory prostate cancer (HRPC) who have failed prior chemotherapy. This filing is based primarily on data from the SPARC Phase 3 registrational trial. "We are delighted that Pharmion has submitted the European marketing application for satraplatin," said Bernd R. Seizinger, M.D., Ph.D., Chief Executive Officer. "With over 60,000 people expected to die from prostate cancer in the European Union this year, there is an urgent need for new therapies. We believe that, if approved, satraplatin has the potential to become an important new treatment option for advanced prostate cancer patients who today have very little hope." GPC Biotech will receive an $8 million milestone payment from Pharmion in connection with EMEA's acceptance of this filing. Under the terms of GPC Biotech's agreement with Spectrum Pharmaceuticals, the acceptance of the MAA by the EMEA will also trigger payments by GPC Biotech to Spectrum in a total amount of $3.2 million, representing a direct milestone payment plus Spectrum's share of the $8 million milestone payment from Pharmion.
AZhttp, Inc. <http://www.azhttp.com/> Biotechnology Marketing <http://www.azhttp.com/2007/04/29/biotechnology/>
